Physician profile
Michael J Ourada
NPI 1427164789
$2,242.97
in general payments reported to CMS, 2019-2025
29 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $192 · 2021: $422 · 2022: $372 · 2023: $562 · 2024: $285 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993 · Debt Forgiveness: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $992.73 |
| Debt Forgiveness | $136.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $382.70 | 2019-2025 | |
| Baxter Healthcare | $233.69 | 2022-2023 | |
| Mylan Specialty L.P. | $172.71 | 2019-2024 | Yupelri |
| Welch Allyn | $136.32 | 2021 | |
| Lilly USA, LLC | $132.69 | 2020-2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $125.24 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $111.22 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.55 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $98.08 | 2020-2025 | Farxiga |
| Eisai INC. | $84.86 | 2021-2022 | |
| Novo Nordisk INC | $84.73 | 2021-2023 | Rybelsus, Ozempic |
| Abbvie INC. | $77.81 | 2022-2025 | |
| Axsome Therapeutics, INC. | $66.38 | 2023-2024 | Auvelity |
| Amgen INC. | $54.77 | 2020-2025 | Evenity, Prolia, Prolia |
| Daiichi Sankyo INC. | $45.32 | 2020-2024 | Injectafer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $41.56 | 2023-2024 | Verquvo, Keytruda |
| Viatris Specialty LLC | $40.70 | 2025 | Yupelri |
| Boston Scientific Corporation | $28.55 | 2025 | Watchman Access System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.24 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $24.98 | 2020-2023 | Trelegy Ellipta |
| Siemens Medical Solutions USA, INC. | $24.76 | 2024 | Mammomat Revelation |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.61 | 2019 | |
| Amarin Pharma, INC. | $23.69 | 2021 | |
| Hydrofera LLC | $21.43 | 2025 | Hydrofera Blue |
| Nestle Healthcare Nutrition INC. | $21.07 | 2022 | |
| Scpharmaceuticals INC. | $19.79 | 2024 | |
| Allergan, INC. | $18.83 | 2020 | |
| Biowound Solutions, INC. | $11.64 | 2025 | Bio-Connekt |
| E.R. Squibb & Sons, L.L.C. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ourada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.